Agilent and SomaLogic said this week that they have entered an agreement to expand access to SomaLogic's SOMAscan protein biomarker discovery platform by placing it in select academic and contract research centers.

According to SomaLogic CEO Larry Gold, the move comes in response to growing demand for the platform, which the company has been offering out of its laboratory on a fee-for-service basis. SomaLogic has run more than 40,000 samples on the platform since launching it two years ago, Gold told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.